Dulaglutide: difference between revisions
Diff·revision 4 → 5·17:11, 3 Nov 2024
Difference between revision 4 and revision 5 of Dulaglutide. 5 lines changed; the page grew by 148 bytes.
| Revision 4 — 02:25, 16 Oct 2024 GastroparesisGwen (talk) give the isoelectric point with the method it was determined by 2,958 bytes +1,048 | Revision 5 — 17:11, 3 Nov 2024 DrTitration (talk) expand §Practical and analytical notes 3,106 bytes +148 | ||
|---|---|---|---|
| 5 | | Architecture = GLP-1 analogue dimer fused to IgG4 Fc | 5 | | Architecture = GLP-1 analogue dimer fused to IgG4 Fc |
| 6 | | Route = Subcutaneous, weekly | 6 | | Route = Subcutaneous, weekly |
| + | 7 | <!-- Properties --> | |
| + | 8 | | Molar mass = ≈59,670 g·mol⁻¹ | |
| + | 9 | | Half-life = ≈90 h | |
| + | 10 | | Bioavailability, SC = ≈47–65% | |
| 7 | }} | 11 | }} |
| 8 | 12 | ||
| ⋮ | ⋮ | ||
| 28 | [[Category:GLP-1 receptor agonists]] | 32 | [[Category:GLP-1 receptor agonists]] |
| 29 | [[Category:Peptide drugs]] | 33 | [[Category:Peptide drugs]] |
| + | 34 | [[Category:Pharmacokinetics]] | |
| 30 | 35 |